Clinical Trial: Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study

U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07187869) titled 'Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study' on Sept. 16.

Brief Summary: The goal of our study is to explore how treatments affect the bone immune microenvironment and determine the best treatment options for patients with metastatic kidney cancer to the bone. This could prevent skeletal complications and improve patient outcomes.

Study Start Date: March 31, 2026

Study Type: INTERVENTIONAL

Condition: Clear Cell Renal Cell Carcinoma

Intervention: DRUG: Cabozantinib

Given by IV

DRUG: Nivolumab

Given by IV

Recruitme...